Diffuse hemispheric gliomas, H3G34R/V-mutant (DHG-H3G34), are lethal brain tumors lacking targeted therapies. They originate from interneuronal precursors; however, leveraging this origin for therapeutic insights remains unexplored. Here, we delineate a cellular hierarchy along the interneuron lineage development continuum, revealing that DHG-H3G34 mirror spatial patterns of progenitor streams surrounding interneuron nests, as seen during human brain development. Integrating these findings with genome-wide CRISPR-Cas9 screens identifies genes upregulated in interneuron lineage progenitors as major dependencies. Among these, CDK6 emerges as a targetable vulnerability: DHG-H3G34 tumor cells show enhanced sensitivity to CDK4/6 inhibitors and a CDK6-specific degrader, promoting a shift toward more mature interneuron-like states, reducing tumor growth, and prolonging xenograft survival. Notably, a patient with progressive DHG-H3G34 treated with a CDK4/6 inhibitor achieved 17 months of stable disease. This study underscores interneuronal progenitor-like states, organized in characteristic niches, as a distinct vulnerability in DHG-H3G34, highlighting CDK6 as a promising clinically actionable target.

Liu, I., Alencastro Veiga Cruzeiro, G., Bjerke, L., Rogers, R. F., Grabovska, Y., Beck, A., Mackay, A., Barron, T., Hack, O. A., Quezada, M. A., Molinari, V., Shaw, M. L., Perez-Somarriba, M., Temelso, S., Raynaud, F., Ruddle, R., Panditharatna, E., Englinger, B., Mire, H. M., Jiang, L., Nascimento, A., Labelle, J., Haase, R., Rozowsky, J., Neyazi, S., Baumgartner, A. -., Castellani, S., Hoffman, S. E., Cameron, A., Morrow, M., Nguyen, Q. -., Pericoli, G., Madlener, S., Mayr, L., Dorfer, C., Geyeregger, R., Rota, C., Ricken, G., Ligon, K. L., Alexandrescu, S., Cartaxo, R. T., Lau, B., Uphadhyaya, S., Koschmann, C., Braun, E., Danan-Gotthold, M., Hu, L., Siletti, K., Sundstrom, E., Hodge, R., Lein, E., Agnihotri, S., Eisenstat, D. D., Stapleton, S., King, A., Bleil, C., Mastronuzzi, A., Cole, K. A., Waanders, A. J., Montero Carcaboso, A., Schuller, U., Hargrave, D., Vinci, M., Carceller, F., Haberler, C., Slavc, I., Linnarsson, S., Gojo, J., Monje, M., Jones, C., Filbin, M. G., GABAergic neuronal lineage development determines clinically actionable targets in diffuse hemispheric glioma, H3G34-mutant, <<CANCER CELL>>, 2024; 42 (9): 1528-1548.e17. [doi:10.1016/j.ccell.2024.08.006] [https://hdl.handle.net/10807/329958]

GABAergic neuronal lineage development determines clinically actionable targets in diffuse hemispheric glioma, H3G34-mutant

Mastronuzzi, Angela
Writing – Original Draft Preparation
;
2024

Abstract

Diffuse hemispheric gliomas, H3G34R/V-mutant (DHG-H3G34), are lethal brain tumors lacking targeted therapies. They originate from interneuronal precursors; however, leveraging this origin for therapeutic insights remains unexplored. Here, we delineate a cellular hierarchy along the interneuron lineage development continuum, revealing that DHG-H3G34 mirror spatial patterns of progenitor streams surrounding interneuron nests, as seen during human brain development. Integrating these findings with genome-wide CRISPR-Cas9 screens identifies genes upregulated in interneuron lineage progenitors as major dependencies. Among these, CDK6 emerges as a targetable vulnerability: DHG-H3G34 tumor cells show enhanced sensitivity to CDK4/6 inhibitors and a CDK6-specific degrader, promoting a shift toward more mature interneuron-like states, reducing tumor growth, and prolonging xenograft survival. Notably, a patient with progressive DHG-H3G34 treated with a CDK4/6 inhibitor achieved 17 months of stable disease. This study underscores interneuronal progenitor-like states, organized in characteristic niches, as a distinct vulnerability in DHG-H3G34, highlighting CDK6 as a promising clinically actionable target.
2024
Inglese
Liu, I., Alencastro Veiga Cruzeiro, G., Bjerke, L., Rogers, R. F., Grabovska, Y., Beck, A., Mackay, A., Barron, T., Hack, O. A., Quezada, M. A., Molinari, V., Shaw, M. L., Perez-Somarriba, M., Temelso, S., Raynaud, F., Ruddle, R., Panditharatna, E., Englinger, B., Mire, H. M., Jiang, L., Nascimento, A., Labelle, J., Haase, R., Rozowsky, J., Neyazi, S., Baumgartner, A. -., Castellani, S., Hoffman, S. E., Cameron, A., Morrow, M., Nguyen, Q. -., Pericoli, G., Madlener, S., Mayr, L., Dorfer, C., Geyeregger, R., Rota, C., Ricken, G., Ligon, K. L., Alexandrescu, S., Cartaxo, R. T., Lau, B., Uphadhyaya, S., Koschmann, C., Braun, E., Danan-Gotthold, M., Hu, L., Siletti, K., Sundstrom, E., Hodge, R., Lein, E., Agnihotri, S., Eisenstat, D. D., Stapleton, S., King, A., Bleil, C., Mastronuzzi, A., Cole, K. A., Waanders, A. J., Montero Carcaboso, A., Schuller, U., Hargrave, D., Vinci, M., Carceller, F., Haberler, C., Slavc, I., Linnarsson, S., Gojo, J., Monje, M., Jones, C., Filbin, M. G., GABAergic neuronal lineage development determines clinically actionable targets in diffuse hemispheric glioma, H3G34-mutant, <<CANCER CELL>>, 2024; 42 (9): 1528-1548.e17. [doi:10.1016/j.ccell.2024.08.006] [https://hdl.handle.net/10807/329958]
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S1535610824003052-main.pdf

accesso aperto

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 2.88 MB
Formato Adobe PDF
2.88 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/329958
Citazioni
  • ???jsp.display-item.citation.pmc??? 29
  • Scopus 39
  • ???jsp.display-item.citation.isi??? 37
social impact